announced a partnership with Mereo BioPharma Group, a specialty biopharmaceutical company. Under this partnership, ICON will be the sole provider of clinical development services to Mereo.

	 Mereo is a new UK company that is focused on acquiring, developing and commercializing medicines that are targeted at rare and specialist disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis and are targeted at brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease and hypogonadotropic hypogonadism.

News

Contract research organization ICON plc announced a partnership with Mereo BioPharma Group, a specialty biopharmaceutical company.